Sugi Predict

Sugi Predict / Compounds / SCHEMBL949468

SCHEMBL949468

SCHEMBL949468

CCCCN1CCCCC1(O)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ S1PR1 P21453 2/20 0.36
▸ S1PR3 Q99500 2/20 0.36
▸ S1PR5 Q9H228 2/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ S1PR4 O95977 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CNR2 P34972 3/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.31
▸ FPR3 P25089 2/20 0.31
▸ FPR2 P25090 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8893030 0.95 S1PR1 (0.36) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL8893018 0.95 S1PR1 (0.36) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL9357038 0.90 S1PR1 (0.39) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL9357045 0.90 S1PR1 (0.39) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL28772993 0.89 S1PR1 (0.41) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL454182 0.89 S1PR1 (0.41) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL10527688 0.89 S1PR1 (0.41) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL9555188 0.89 S1PR1 (0.41) L3MBTL1S1PR1S1PR3S1PR5KMT2A
SCHEMBL456427 0.87 S1PR1 (0.40) L3MBTL1S1PR1S1PR3S1PR5S1PR4
SCHEMBL8894194 0.84 BDKRB2 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865369-B1 Solid dispersions of isoxazoline compounds SUMITOMO CHEMICAL CO (JP) 2023-05-24 — — EP disclosed
CN-107406458-B Antiparasitic compounds 爱维斯塔制药解决方案有限公司 2021-01-05 — — CN disclosed
US-10807992-B2 Single enantiomer antiparasitic compounds AVISTA PHARMA SOLUTIONS, INC. (US) 2020-10-20 — — US disclosed
EP-3710453-A1 SINGLE ENANTIOMER ANTIPARASITIC COMPOUNDS Avista Pharma Solutions, Inc. (US) 2020-09-23 — — EP disclosed
US-10772331-B2 Antiparasitic compounds AVISTA PHARMA SOLUTIONS, INC. (US) 2020-09-15 — — US disclosed
EP-3245209-B1 ANTIPARASITIC COMPOUNDS AVISTA PHARMA SOLUTIONS INC (US) 2020-07-29 — — EP disclosed
US-20200181134-A1 Antiparasitic Compounds CAMBREX CHARLES CITY, INC. 2020-06-11 — — US disclosed
US-10556909-B2 Synthetic process and intermediates AVISTA PHARMA SOLUTIONS, INC. (US) 2020-02-11 — — US disclosed
US-20190284199-A1 Synthetic Process and Novel Intermediates BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2019-09-19 — — US disclosed
US-20190274305-A1 ANTIPARASITIC COMPOUNDS SNAPDRAGON CHEMISTRY, INC. 2019-09-12 — — US disclosed
WO-2001040206-A1 PESTICIDAL N-HETEROARYL ALPHA-ALKOXIMINO-CARBOXAMIDES NOVARTIS AG (CH) 2001-06-07 — — WO disclosed
WO-2001036367-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2001-05-25 — — WO disclosed
WO-2001036415-A1 PESTICIDAL AMINOHETEROCYCLAMIDE COMPOUNDS NOVARTIS AG (CH) 2001-05-25 — — WO disclosed
WO-2001036372-A1 ORGANIC COMPOUNDS AND THEIR USE IN THE CONTROL OF ECTOPARASITES NOVARTIS AG (CH) 2001-05-25 — — WO disclosed
WO-2001036371-A1 CARBONIC ACID DERIVATIVES AND THEIR USE AS ECTOPARASITICIDAL COMPOSITION NOVARTIS AG (CH) 2001-05-25 — — WO disclosed
WO-2001015684-A2 ANTIMYCOTIC DRUG NOVARTIS AG (CH) 2001-03-08 — — WO disclosed
WO-2000073310-A1 4-SUBSTITUTED MILBEMYCIN DERIVATIVES NOVARTIS AG (CH) 2000-12-07 — — WO disclosed
WO-2000058291-A1 PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES NOVARTIS AG (CH) 2000-10-05 — — WO disclosed
WO-2000042047-A1 4-PHENOXYMETHYL-SUBSTITUTED MILBEMYCINS NOVARTIS AG (CH) 2000-07-20 — — WO disclosed
WO-2000029378-A2 ACYCLIC AND CYCLIC GUANIDINE- AND ACETAMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PESTICIDES, ESP. AS PARASITICIDES NOVARTIS AG (CH) 2000-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284199-A1 Synthetic Process and Novel Intermediates SBDS, LSS, NISCH L3MBTL1 3681/4885S1PR1 2156/4885S1PR3 2460/4885
US-20200181134-A1 Antiparasitic Compounds ACHE, DDT, NISCH L3MBTL1 739/4885S1PR1 1108/4885S1PR3 1032/4885
US-10807992-B2 Single enantiomer antiparasitic compounds DDT, ACHE, NISCH L3MBTL1 207/4885S1PR1 667/4885S1PR3 964/4885
US-10556909-B2 Synthetic process and intermediates SBDS, NISCH, SQOR L3MBTL1 3770/4885S1PR1 2203/4885S1PR3 2584/4885
US-10772331-B2 Antiparasitic compounds ACHE, DDT, NISCH L3MBTL1 739/4885S1PR1 1108/4885S1PR3 1032/4885
US-20190274305-A1 ANTIPARASITIC COMPOUNDS ACHE, DDT, NISCH L3MBTL1 739/4885S1PR1 1108/4885S1PR3 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.